Dora I. Molina

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Eva Lonn, Jackie Bosch, Patricio López‐Jaramillo et al. · New England Journal of Medicine · 2016 · 618 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

The Changing Landscape for Stroke Prevention in AF

Menno V. Huisman, Kenneth J. Rothman, Miney Paquette et al. · Journal of the American College of Cardiology · 2017 · 281 citations · Full text

Medicine, Cardiology, Pharmacotherapy +10